Claim passport · AB-SEMA-US-001

Semaglutide approval belongs to specific products and labels.

The ingredient name alone does not tell a reader whether a product is approved, compounded, counterfeit, appropriately prescribed, or supported for a particular use.

Jurisdiction United StatesLast source check September 18, 2026Version 1.0Review state Editorially reviewed; clinical review pending

Bounded claim

FDA approval applies to named semaglutide drug products for defined indications, formulations, strengths, and labeling conditions; it does not transfer to every product marketed as semaglutide.

What is established

  • FDA-approved semaglutide products have product-specific prescribing information.
  • FDA distinguishes approved products from compounded drugs, which are not FDA approved.
  • Patients and clinicians need the actual product identity and label context, not only the ingredient name.

What this record does not do

  • Recommend a product, dose, titration, route, or treatment.
  • Determine whether compounded medication is appropriate for an individual.
  • Authenticate a vial, seller, pharmacy, or online listing.

Source trail

Review and limitations

Editorial review: AminoBrief publishing team, source and scope check completed September 18, 2026. Qualified clinical reviewer: not yet assigned. This page is educational and does not replace a product label or advice from a licensed professional.

Correction history: none. Report a correction.